Analysts have been eager to weigh in on the Healthcare sector with new ratings on Innate Pharma SA (IPHYF – Research Report) and Medios AG (MEDOF – Research Report).
Innate Pharma SA (IPHYF)
Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA on November 14 and set a price target of EUR3.10. The company’s shares closed last Tuesday at $2.39, close to its 52-week low of $2.16.
According to TipRanks.com, Telliez is ranked #7948 out of 8631 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Innate Pharma SA with a $3.31 average price target.
See today’s best-performing stocks on TipRanks >>
Medios AG (MEDOF)
Kepler Capital analyst Allegre Ludovic maintained a Buy rating on Medios AG on November 14 and set a price target of EUR30.00. The company’s shares closed last Wednesday at $50.00.
According to TipRanks.com, Ludovic is ranked #8408 out of 8631 analysts.
Medios AG has an analyst consensus of Moderate Buy, with a price target consensus of $39.01, a -22.0% downside from current levels. In a report issued on November 10, Warburg Research also reiterated a Buy rating on the stock with a EUR43.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IPHYF:
